Monograph Details
|
|
Hematology
> Bleeding disorders
|
|
CYKLOKAPRON |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Plasminogen activation inhibitor. |
| Generic Name |
|
Tranexamic acid 100mg/mL; soln for IV inj. |
| Indications |
|
Short-term use in hemophilia to reduce or prevent hemorrhage, and reduce the need for replacement therapy during and following tooth extraction. |
| Adults and Children |
|
Give by IV inj. Max injection rate: 1mL/min. Pre-extraction: 10mg/kg; post-op: 10mg/kg 3–4 times daily for 2–8 days. Renal impairment: serum creatinine 1.36–2.83mg/dL: 10mg/kg twice daily; 2.83–5.66mg/dL: 10mg/kg once daily; >5.66mg/dL: 10mg/kg every 48hrs or 5mg/kg every 24 hours. |
| Contraindications |
|
Acquired defective color vision. Subarachnoid hemorrhage. Active intravascular clotting. |
| Precautions |
|
Therapy longer than several days: do ophthalmologic exam (before and during); discontinue if visual changes occur. Renal insufficiency; reduce dose. History of thromboembolic disease. Disseminated intravascular coagulation. Upper urinary tract bleeding. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Avoid concomitant Factor IX complex concentrates or Anti-inhibitor Coagulant concentrates; increased risk of thrombosis. Do not mix with solutions containing penicillin. |
| Adverse Reactions |
|
GI upset, giddiness, hypotension, visual abnormalities; rare: thromboembolic events. |
| How Supplied |
|
Amps (10mL)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
